Negotiable
The date of payment from buyers deliver within days
Beijing
Long-term effective
2022-08-03 05:35
327
Company Profile
Chengdu VACURE Biotechnology Co., LtdBy certification [File Integrity]
Contact:wksw888(Mr.)
Email:
Telephone:
Phone:
Area:Beijing
Address:Beijing
Website:http://www.vacurebiotech.com/ http://wksw888.teyiart.com/
Intended use
This device is intended to be used for the in vitro quantitative determination of Serum Amyloid A (SAA) in human whole blood, serum or plasma. And it is for professional use only, not for self-testing of untrained individuals, nor for near-patient testing.
Summary
Serum amyloid A (hereafter referred to as SAA) is an acute-phase protein whose concentration in the blood can rise sharply within hours during inflammatory, infectious and non-infectious diseases. The increase can reach 10-1000 times the normal value. After clearing the pathogen, it can be quickly reduced to normal level, which is a sensitive indicator reflecting the infection status of the body and the recovery of inflammation. Similar to C-reactive protein (hereafter referred to as CRP), the detection of SAA is helpful in diagnosing inflammation, assessing its activity, monitoring its activity, and treatment. However, it is more conclusive than the CRP test in diagnosing patients with viral infection, renal transplant rejection (especially those on immunosuppressive therapy), and patients with cystic fibrosis treated with corticosteroids. In the early diagnosis of infectious diseases, the combined detection of SAA and CRP can provide early identification of viral and bacterial infections. When SAA and CRP increase at the same time, it indicates the possibility of bacterial infection; if SAA increases but CRP does not increase, it indicates the possibility of viral infection. Simultaneous detection of CRP and SAA can improve the sensitivity of infection diagnosis. SAA is associated with high-density lipoprotein (HDL), which regulates high-density lipoprotein (HDL) metabolism during inflammation. A particularly important property of SAA is that its degradation products can be deposited in various organs in the form of amyloid A (AA) fibrils, which is a serious complication in chronic inflammatory diseases. The study found that in cases of inflammatory arthritis, SAA was most strongly associated with disease activity. For patients with amyloid A amyloidosis, treatment aimed at restoring serum amyloid A levels to normal can improve the condition.
The current clinical methods for detecting SAA include chemiluminescence, immunochromatography and so on.
TEST INFORMATION | |||
Method |
Microfluidic Fluorescent Immunoassay |
Test |
LYOFIA® SAA |
Format |
Cassette |
Reaction Time |
5min |
Linearity |
0.5~100mg/L |
Reference Interval |
≤6.4mg/L |
Sample |
WB / S / P |
Certificate |
CE/NMPA |
ORDERING | |||||
Cat. No. |
LMIFSA25 |
Applicable analyzer |
LYOFIA-I, LYOFIA 8, |
Kit Size |
25T |
Cat. No. |
LAIFSA25 |
Applicable analyzer |
LYOFIA 100 (Full-Automatic) |
Kit Size |
25T |
Hospitals
Laboratory
Clinics
Ambulance
Cardiology
Pediatrics
Emergency
CSC
Q: Reagent expiration date?
A: 12 months.
Q: Can I apply for free reagent samples?
A: Yes.
Q: Can the quality control materials of the reagents be purchased?
A: Yes.
Q: Can reagents from different batches be mixed?
A: No
http://www.vacurebiotech.com/